Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

CHART/TABLE: Old Dog, New Tricks: Label Expansions Invigorate Diabetic Nephropathy Market

Wed, 02/13/2019 - 7:35am

With four new entrants readying to be prescribed in the next four years, the market for diabetic nephropathy is looking...

      Related Stories 

Sun’s Ilumya Gnaws At US Psoriasis Market

Wed, 02/13/2019 - 12:48am

Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian...

      Related Stories 

Q4 Preview: How Will Bayer Survive Patent Cliff?

Tue, 02/12/2019 - 11:02pm

Ahead of the German major's fourth-quarter earnings call Feb. 27, analysts at Bernstein have been weighing up Bayer's chances of...

      Related Stories 

China - The Next Promised Land For Korean Biosimilars?

Tue, 02/12/2019 - 4:55pm

Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market...

      Related Stories 

In NASH, Gilead Swung For The Fences And Struck Out Again

Tue, 02/12/2019 - 12:57pm

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend...

      Related Stories 

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

Tue, 02/12/2019 - 7:06am

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with...

      Related Stories 

Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal

Tue, 02/12/2019 - 6:26am

Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.

      Related Stories 

China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

Tue, 02/12/2019 - 5:19am

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule...

      Related Stories 

Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo

Tue, 02/12/2019 - 4:40am

The move follows a similar price cut for Amgen's competing PCSK9 inhibitor Repatha and comes as PBMs, including UnitedHealth Group's...

      Related Stories 

Asia Executives On The Move: EdiGene, Teijin, Astellas

Mon, 02/11/2019 - 9:27pm

New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while...

      Related Stories 

Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III

Mon, 02/11/2019 - 1:29pm

Primary endpoint miss for Phase III selonsertib in cirrhotic NASH patients follows disappointing data at both 2018 major liver conferences...

      Related Stories 

UniQure Has High HOPE For Hemophilia B Gene Therapy

Mon, 02/11/2019 - 6:39am

The Dutch company's update on AMT-061 and the initiation of a pivotal trial called HOPE-B of around 50 patients could...

      Related Stories 

API Sector In India No Longer ‘Poor Cousin’ Of Formulations

Mon, 02/11/2019 - 5:12am

The active pharmaceuticals ingredients segment in India appears to be coming into its own, alongside signs of a revival in...

      Related Stories 

Pages